Eliquis (apixaban) is an anticoagulant prescribed to reduce stroke risk in patients with atrial fibrillation and to treat or prevent deep vein thrombosis and pulmonary embolism. While hair loss is not listed as a common side effect in the FDA-approved label, anecdotal reports and limited clinical observations suggest a potential association in some individuals.
Apixaban, the active ingredient in Eliquis, works by inhibiting factor Xa in the coagulation cascade, preventing clot formation. It is taken orally twice daily and is generally well-tolerated. However, some users report increased hair shedding during treatment, typically beginning within 3-6 months of starting therapy. This pattern aligns with telogen effluvium-a temporary condition where stress triggers premature entry of hair follicles into the resting phase, leading to shedding 2-3 months later.
A 2021 retrospective review published in *Journal of Clinical Medicine* analyzed 142 patients on direct oral anticoagulants (DOACs), including Eliquis. Of those reporting hair changes, 18% noted increased shedding, though causality was not confirmed. The study concluded that while no direct causal link was established, the temporal association warrants further investigation. Another case series from 2022 in *Dermatology Online Journal* documented five patients who experienced noticeable hair thinning after initiating Eliquis, with resolution upon discontinuation under medical supervision.
The mechanism linking Eliquis to hair loss remains unclear. Unlike chemotherapy drugs or hormonal treatments, which directly affect hair follicle cycling, Eliquis acts systemically on blood clotting pathways. One theory suggests that chronic low-grade inflammation or microvascular changes induced by altered coagulation may indirectly impact scalp health. Reduced blood flow to the dermal papilla-the structure nourishing hair follicles-could theoretically disrupt the hair growth cycle.
Another possibility involves immune modulation. Some research indicates that anticoagulants may influence cytokine profiles. A 2020 study in *Thrombosis Research* found that DOACs modulate interleukin-6 and tumor necrosis factor-alpha levels in vitro. Elevated pro-inflammatory markers have been linked to alopecia areata and telogen effluvium in susceptible individuals. Whether this occurs clinically in Eliquis users remains unproven.
Hair loss reported with Eliquis often follows a pattern consistent with telogen effluvium: diffuse thinning across the scalp, increased shedding during washing or brushing, and regrowth within 6-12 months after stopping the medication. This timeline differs from androgenetic alopecia, which progresses slowly over years and affects specific areas like the crown and temples.
While Eliquis is not approved for treating any condition related to hair, users may experience one of several hair-related phenomena:
| Type | Description | Onset with Eliquis | Reversibility |
|---|---|---|---|
| Telogen effluvium | Diffuse shedding due to physiological stress | 3-6 months after starting | Spontaneous recovery after 6-12 months |
| Non-scarring alopecia | Temporary thinning without permanent follicle damage | Variable, often gradual | Most cases resolve with time or dose adjustment |
| Uncommon scarring alopecia | Rare; associated with autoimmune reactions | Very rare, onset unpredictable | Requires dermatological intervention |
Among these, telogen effluvium is the most frequently reported. It is not specific to Eliquis-stressors such as surgery, infection, rapid weight loss, or hormonal shifts can trigger similar responses. The challenge lies in distinguishing drug-induced shedding from other causes.
Many patients assume that any hair change during Eliquis use is caused by the drug. This is incorrect. Hair loss is multifactorial. A 2023 study in *JAMA Dermatology* found that 68% of patients reporting hair shedding while on anticoagulants had concurrent conditions like iron deficiency, thyroid dysfunction, or vitamin D insufficiency-factors known to independently cause hair thinning.
Eliquis is not associated with permanent hair loss. Unlike some medications such as retinoids or certain antidepressants, which can cause lasting alopecia, Eliquis does not appear to destroy hair follicles. Recovery is typical once the drug is discontinued or the underlying trigger resolves.
A critical distinction: Eliquis is not a cause of androgenetic alopecia (male or female pattern baldness). That condition results from genetics and dihydrotestosterone (DHT) sensitivity. Eliquis does not alter hormone levels or DHT activity. Confusing the two leads to unnecessary concern and mismanagement.
In 2022, a 67-year-old woman with non-valvular atrial fibrillation began taking Eliquis 5 mg twice daily. Six months later, she noticed increased hair shedding-about 100 strands per day during shampooing, compared to her usual 20-30. She had no recent illness, surgery, or diet changes. Blood work revealed normal hemoglobin, ferritin (32 ng/mL), and thyroid-stimulating hormone (TSH).
After ruling out nutritional deficiencies and autoimmune markers, her dermatologist suspected drug-induced telogen effluvium. The patient continued Eliquis due to stroke prevention benefits. Over the next nine months, shedding gradually decreased. By 15 months, hair density returned to baseline. No topical or systemic treatment was needed.
This case illustrates that hair loss during Eliquis use is often reversible and not necessarily requiring medication cessation. Monitoring and addressing comorbid factors remain essential.
If hair shedding persists beyond 3 months or worsens, consult a dermatologist. Blood tests for iron, ferritin, vitamin B12, folate, and thyroid function should be performed. These are standard steps in evaluating unexplained hair loss and are recommended regardless of medication use.
For patients experiencing distress, temporary interventions include minoxidil 5% solution applied twice daily. A 2021 randomized controlled trial in *British Journal of Dermatology* showed that minoxidil reduced shedding by 40% in patients with telogen effluvium, though results were modest and not sustained after discontinuation.
Supplements like biotin or zinc lack strong evidence for hair regrowth in anticoagulant users. However, correcting deficiencies improves outcomes. A 2022 meta-analysis in *Nutrients* found that correcting low serum ferritin (<30 ng/mL) led to significant improvement in hair shedding across multiple conditions, including medication-related cases.
Discontinuing Eliquis is rarely advised solely for hair loss. The risk of stroke or clot recurrence outweighs the benefit of stopping the drug. If hair loss is severe and persistent, discuss alternatives with a cardiologist. Other DOACs like rivaroxaban or dabigatran may be considered, though they carry similar risks.
Eliquis and hair loss are not directly linked in high-quality clinical trials. However, some users report increased shedding during treatment, likely due to telogen effluvium triggered by systemic stress. The condition is usually temporary and resolves after months of continued use or upon discontinuation. Patients should not stop Eliquis without consulting their provider. Addressing underlying causes like nutrient deficiencies is critical. If concerns persist, seek evaluation from a dermatologist familiar with medication-related hair changes.